This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

FDA Advisory Committee Recommends ThromboGenics' Ocriplasmin For The Treatment Of Symptomatic Vitreomacular Adhesion (VMA)

LEUVEN, Belgium, July 27, 2012 /PRNewswire/ --

- ThromboGenics to hold conference call to discuss the panel recommendation

ThromboGenics NV (Euronext Brussels: THR), a biopharmaceutical company focused on developing innovative ophthalmic medicines, today announces that the US Food and Drug Administration (FDA) Dermatologic and Ophthalmic Drugs Advisory Committee has recommended that the FDA grant ocriplasmin approval for the treatment of symptomatic Vitreomacular Adhesion (VMA). The Committee voted 10 to 0 at its meeting held yesterday that the benefits of administering ocriplasmin for the treatment of vitreomacular adhesions outweigh the potential risks.

The recommendation of the Advisory Committee will form part of the FDA's overall assessment of the ocriplasmin Biologics License Application (BLA). The FDA has assigned the ocriplasmin BLA a Prescription Drug User Fee Act (PDUFA) goal date of 17 October, 2012.

Dr Patrik De Haes, ThromboGenics '  CEO, said: "We are pleased that the Advisory Committee has made a positive recommendation supporting the approval of ocriplasmin for the treatment of symptomatic VMA. We will continue to work with the FDA as it completes its assessment of the ocriplasmin BLA. Symptomatic VMA is an area of unmet medical need and ThromboGenics is looking forward to making this novel treatment option available to the many patients in the U.S. who could benefit."      

Symptomatic VMA is a progressive condition that if left untreated frequently leads to retinal distortion, further deterioration in vision and has the potential to cause irreversible damage and complications. Market surveys conducted by ThromboGenics suggest that there are approximately 500,000 patients in the U.S. and the major markets of the EU who could potentially benefit from ocriplasmin annually. If approved, ocriplasmin will be the first pharmacological treatment for symptomatic VMA.

A conference call for analysts, press and investors will be hosted by Dr Patrik De Haes, CEO of ThromboGenics, on Friday, 27 July at 15:00 CET ( 09:00 ET).

The dial-in numbers and Participant Passcode for the call are set out below:

    Belgium                         +32-27-920-435 / 0800-74656 (Toll Free)
    UK                              +44(0)20-3003-2666 / 0808-109-0700 (Toll Free)
    USA                             +1-866-966-5335 (Toll Free)
    
    Participant Passcode:           7290677

We request that participants dial in 5-10 minutes prior to the start time of 15:00 CET ( 09:00 ET). There will be a replay of the call available shortly after the call which will be accessible for seven days. Click here for international replay numbers followed by the Access Pin 7290677.

For further information please contact:

 
                                         
    ThromboGenics                        
    Dr. Patrik De Haes, CEO                  Tel: +32-16-75-13-10
                                             patrik.dehaes@thrombogenics.com

    Chris Buyse, CFO                         Tel: +32-16-75-13-10
                                             chris.buyse@thrombogenics.com
 
    Citigate Dewe Rogerson               
    David Dible/ Nina Enegren/ Sita Shah     Tel: +44-20-7638-9571
                                             sita.shah@citigatedr.co.uk
    The Trout Group                      
    Todd James/ Simon Harnest                Tel: +1-646-378-2926
                                             tjames@troutgroup.com

About ThromboGenics

1 of 3

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
SYM TRADE IT LAST %CHG

Markets

DOW 17,826.30 -279.47 -1.54%
S&P 500 2,081.18 -23.81 -1.13%
NASDAQ 4,931.8150 -75.9760 -1.52%

Partners Compare Online Brokers

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs